308 related articles for article (PubMed ID: 24565764)
21. Rapid desensitization of hypersensitivity reactions to chemotherapy agents.
Castells M
Curr Drug Saf; 2006 Aug; 1(3):243-51. PubMed ID: 18690934
[TBL] [Abstract][Full Text] [Related]
22. Outcomes and safety of rapid desensitization for chemotherapy hypersensitivity.
Limsuwan T; Castells MC
Expert Opin Drug Saf; 2010 Jan; 9(1):39-53. PubMed ID: 20001753
[TBL] [Abstract][Full Text] [Related]
23. Rapid desensitization for hypersensitivity reactions to medications.
Castells M
Immunol Allergy Clin North Am; 2009 Aug; 29(3):585-606. PubMed ID: 19563999
[TBL] [Abstract][Full Text] [Related]
24. A new non-dilution rapid desensitization protocol successfully applied to all-grade platinum hypersensitivity.
Chung SJ; Kang SY; Kang RY; Kim YC; Lee KH; Kim TY; Han SW; Kang HR
Cancer Chemother Pharmacol; 2018 Nov; 82(5):777-785. PubMed ID: 30105458
[TBL] [Abstract][Full Text] [Related]
25. Platinum Chemotherapy Hypersensitivity: Prevalence and Management.
Otani IM; Wong J; Banerji A
Immunol Allergy Clin North Am; 2017 Nov; 37(4):663-677. PubMed ID: 28965633
[TBL] [Abstract][Full Text] [Related]
26. Review of hypersensitivity reactions to antineoplastic agents.
Cortijo-Cascajares S; Jiménez-Cerezo MJ; Herreros de Tejada A
Farm Hosp; 2012; 36(3):148-58. PubMed ID: 22484106
[TBL] [Abstract][Full Text] [Related]
27. Evaluation and management of hypersensitivity reactions to chemotherapy agents.
Tham EH; Cheng YK; Tay MH; Alcasabas AP; Shek LP
Postgrad Med J; 2015 Mar; 91(1073):145-50. PubMed ID: 25659930
[TBL] [Abstract][Full Text] [Related]
28. Desensitization to lenograstim after a life- threatening reaction to filgrastim.
Nuñez-Acevedo B; Rodríguez-Jiménez B; Domínguez-Ortega J; González-Montellano E; Ibáñez-Heras N; Enrech-Francés S
J Investig Allergol Clin Immunol; 2015; 25(2):158-60. PubMed ID: 25997320
[No Abstract] [Full Text] [Related]
29. Nonallergic drug hypersensitivity reactions.
Farnam K; Chang C; Teuber S; Gershwin ME
Int Arch Allergy Immunol; 2012; 159(4):327-45. PubMed ID: 22832422
[TBL] [Abstract][Full Text] [Related]
30. The Effects of Prolonged Infusion on Reducing Oxaliplatin Hypersensitivity Reactions.
Zhang X; Zhao Y; Zheng Y; Dong Y
J Investig Allergol Clin Immunol; 2017; 27(1):65-66. PubMed ID: 28211349
[No Abstract] [Full Text] [Related]
31. Protocols for drug allergy desensitization in children.
Diaferio L; Giovannini M; Clark E; Castagnoli R; Caimmi D
Expert Rev Clin Immunol; 2020 Jan; 16(1):91-100. PubMed ID: 31771366
[No Abstract] [Full Text] [Related]
32. Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies.
Sloane D; Govindarajulu U; Harrow-Mortelliti J; Barry W; Hsu FI; Hong D; Laidlaw T; Palis R; Legere H; Bunyavanich S; Breslow R; Wesemann D; Barrett N; Brennan P; Chong HJ; Liu A; Fernandez J; Fanning L; Kyin T; Cahill K; Bankova L; Lynch A; Berlin S; Campos S; Fuchs C; Mayer R; Matulonis U; Castells M
J Allergy Clin Immunol Pract; 2016; 4(3):497-504. PubMed ID: 26895621
[TBL] [Abstract][Full Text] [Related]
33. Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies.
Robinson JB; Singh D; Bodurka-Bevers DC; Wharton JT; Gershenson DM; Wolf JK
Gynecol Oncol; 2001 Sep; 82(3):550-8. PubMed ID: 11520154
[TBL] [Abstract][Full Text] [Related]
34. Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions.
Lee CW; Matulonis UA; Castells MC
Gynecol Oncol; 2004 Nov; 95(2):370-6. PubMed ID: 15491759
[TBL] [Abstract][Full Text] [Related]
35. Drug Hypersensitivity: Broadening Horizons.
Tilles SA
Immunol Allergy Clin North Am; 2017 Nov; 37(4):xv-xvi. PubMed ID: 28965643
[No Abstract] [Full Text] [Related]
36. General considerations on rapid desensitization for drug hypersensitivity - a consensus statement.
Cernadas JR; Brockow K; Romano A; Aberer W; Torres MJ; Bircher A; Campi P; Sanz ML; Castells M; Demoly P; Pichler WJ;
Allergy; 2010 Nov; 65(11):1357-66. PubMed ID: 20716314
[TBL] [Abstract][Full Text] [Related]
37. Breakthrough reactions during rapid drug desensitization: Clinical outcome and risk factors.
Kang Y; Kwon OY; Jung H; Kang M; An J; Lee JH; Won HK; Song WJ; Kwon HS; Cho YS; Moon HB; Kim TB
Ann Allergy Asthma Immunol; 2019 Jul; 123(1):48-56.e1. PubMed ID: 31108181
[TBL] [Abstract][Full Text] [Related]
38. Hypersensitivity reactions to oxaliplatin: cross-reactivity to carboplatin and the introduction of a desensitization schedule.
Meyer L; Zuberbier T; Worm M; Oettle H; Riess H
J Clin Oncol; 2002 Feb; 20(4):1146-7. PubMed ID: 11844841
[No Abstract] [Full Text] [Related]
39. Current Knowledge and Management of Hypersensitivity Reactions to Monoclonal Antibodies.
Picard M; Galvão VR
J Allergy Clin Immunol Pract; 2017; 5(3):600-609. PubMed ID: 28110056
[TBL] [Abstract][Full Text] [Related]
40. An approach to natalizumab hypersensitivity: a case series of induction of tolerance.
Camacho-Halili M; George R; Gottesman M; Davis-Lorton M
Mult Scler; 2011 Feb; 17(2):250-3. PubMed ID: 21177321
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
